20.52
price down icon1.39%   -0.29
after-market アフターアワーズ: 21.22 0.70 +3.41%
loading
前日終値:
$20.81
開ける:
$21.09
24時間の取引高:
1.10M
Relative Volume:
0.57
時価総額:
$1.82B
収益:
$217.42M
当期純損益:
$-243.25M
株価収益率:
-7.3412
EPS:
-2.7952
ネットキャッシュフロー:
$-278.35M
1週間 パフォーマンス:
-7.94%
1か月 パフォーマンス:
-3.71%
6か月 パフォーマンス:
-3.71%
1年 パフォーマンス:
+113.08%
1日の値動き範囲:
Value
$20.50
$21.57
1週間の範囲:
Value
$20.50
$22.74
52週間の値動き範囲:
Value
$9.42
$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name
名前
Syndax Pharmaceuticals Inc
Name
セクター
Healthcare (1074)
Name
電話
781-419-1400
Name
住所
730 THIRD AVENUE, NEW YORK, MA
Name
職員
298
Name
Twitter
@syndax
Name
次回の収益日
2026-08-03
Name
最新のSEC提出書
Name
SNDX's Discussions on Twitter

Compare SNDX vs VRTX, REGN, ARGX, RVMD, ALNY

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
SNDX icon
SNDX
Syndax Pharmaceuticals Inc
20.52 1.84B 217.42M -243.25M -278.35M -2.7952
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
479.00 121.16B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
667.17 68.78B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
888.82 57.44B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
188.07 40.23B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.40 36.28B 4.29B 577.22M 641.34M 4.2086

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-10-16 再開されました H.C. Wainwright Buy
2025-09-10 再開されました Stifel Buy
2025-09-04 再開されました Guggenheim Buy
2025-08-05 繰り返されました BTIG Research Buy
2025-07-10 開始されました Goldman Buy
2024-10-24 開始されました UBS Buy
2024-06-28 開始されました Jefferies Buy
2024-01-31 ダウングレード Scotiabank Sector Outperform → Sector Perform
2023-12-22 開始されました Mizuho Buy
2023-10-25 開始されました BofA Securities Buy
2023-10-11 開始されました Goldman Buy
2023-07-27 開始されました Scotiabank Sector Outperform
2023-07-11 開始されました Guggenheim Buy
2023-04-17 再開されました BTIG Research Buy
2023-01-31 開始されました Stifel Buy
2023-01-03 開始されました JP Morgan Overweight
2022-07-28 再開されました B. Riley Securities Buy
2022-04-11 開始されました H.C. Wainwright Buy
2022-02-15 開始されました Goldman Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-05-25 開始されました Citigroup Buy
2021-02-18 開始されました B. Riley Securities Buy
2020-12-03 開始されました Stifel Buy
2020-05-22 アップグレード Citigroup Neutral → Buy
2020-05-22 ダウングレード H.C. Wainwright Buy → Neutral
2020-05-18 ダウングレード Citigroup Buy → Neutral
2020-05-11 繰り返されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-13 繰り返されました H.C. Wainwright Buy
2019-03-08 繰り返されました H.C. Wainwright Buy
2019-01-04 開始されました Robert W. Baird Outperform
2018-01-05 開始されました B. Riley FBR, Inc. Buy
2017-03-16 開始されました FBR & Co. Outperform
2017-03-02 開始されました Instinet Buy
2016-10-07 開始されました Guggenheim Buy
2016-03-28 開始されました Citigroup Buy
2016-03-28 開始されました JMP Securities Mkt Outperform
2016-03-28 開始されました Morgan Stanley Overweight
すべてを表示

Syndax Pharmaceuticals Inc (SNDX) 最新ニュース

pulisher
09:19 AM

Syndax Pharmaceuticals Inc (SNDX) Cash Flow - TradingKey

09:19 AM
pulisher
09:04 AM

Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis - TradingKey

09:04 AM
pulisher
06:32 AM

Syndax Pharmaceuticals (SNDX) Projected to Announce Quarterly Earnings on Monday - MarketBeat

06:32 AM
pulisher
06:16 AM

Orbimed Advisors LLC Invests $22.48 Million in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

06:16 AM
pulisher
Jul 26, 2026

SNDX|Syndax Pharmaceuticals Inc|Price:20.810|Chg%:-0.400 - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Jul 26, 2026
pulisher
Jul 25, 2026

Syndax Pharmaceuticals Inc (SNDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Granahan Investment Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Jul 25, 2026
pulisher
Jul 24, 2026

Price to sales forward of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

Syndax Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SNDX - TradingView

Jul 24, 2026
pulisher
Jul 21, 2026

Syndax Pharmaceuticals Inc. (SNDX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks

Jul 21, 2026
pulisher
Jul 21, 2026

Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily

Jul 21, 2026
pulisher
Jul 21, 2026

Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $37 - Moomoo

Jul 21, 2026
pulisher
Jul 21, 2026

Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst - The Globe and Mail

Jul 21, 2026
pulisher
Jul 19, 2026

Syndax Pharmaceuticals (SNDX) FDA Announcement Summary - Quartr

Jul 19, 2026
pulisher
Jul 19, 2026

Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr

Jul 19, 2026
pulisher
Jul 18, 2026

Syndax Pharmaceuticals Inc. (SNDX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks

Jul 18, 2026
pulisher
Jul 17, 2026

Syndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should Know - Yahoo! Finance Canada

Jul 17, 2026
pulisher
Jul 17, 2026

Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story - Sahm

Jul 17, 2026
pulisher
Jul 17, 2026

SNDX Stock Price, Quote & Chart - ChartMill

Jul 17, 2026
pulisher
Jul 16, 2026

Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo

Jul 16, 2026
pulisher
Jul 16, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail

Jul 16, 2026
pulisher
Jul 16, 2026

TD Cowen Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating - Moomoo

Jul 16, 2026
pulisher
Jul 15, 2026

SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus

Jul 15, 2026
pulisher
Jul 15, 2026

Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $46 - Moomoo

Jul 15, 2026
pulisher
Jul 15, 2026

Syndax Pharmaceuticals unveils new pipeline candidates - BioWorld News

Jul 15, 2026
pulisher
Jul 15, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Jul 15, 2026
pulisher
Jul 15, 2026

H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada

Jul 15, 2026
pulisher
Jul 15, 2026

Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $57 - Moomoo

Jul 15, 2026
pulisher
Jul 15, 2026

Syndax Showcases Late-Stage Pipeline, Expands R&D Strategy - TipRanks

Jul 15, 2026
pulisher
Jul 14, 2026

SNDX6417984 Bond Coupon Profile — Rate & Payments - TradingView

Jul 14, 2026
pulisher
Jul 14, 2026

Syndax Pharmaceuticals Inc to Host R&D Day Transcript - GuruFocus

Jul 14, 2026
pulisher
Jul 14, 2026

SNDX6417984 Bond Profile — Key Metrics - TradingView

Jul 14, 2026
pulisher
Jul 14, 2026

A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX) - Seeking Alpha

Jul 14, 2026
pulisher
Jul 14, 2026

Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push - MarketBeat

Jul 14, 2026
pulisher
Jul 14, 2026

Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead TherapiesSlideshow (NASDAQ:SNDX) 2026-07-14 - Seeking Alpha

Jul 14, 2026
pulisher
Jul 14, 2026

Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Yahoo! Finance Canada

Jul 14, 2026
pulisher
Jul 14, 2026

SNDX: New pipeline assets and late-stage programs drive clinical and commercial growth through 2027 - TradingView

Jul 14, 2026
pulisher
Jul 14, 2026

Syndax (NASDAQ: SNDX) details pipeline expansion and 2026-27 clinical catalysts - Stock Titan

Jul 14, 2026
pulisher
Jul 14, 2026

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event - The Manila Times

Jul 14, 2026
pulisher
Jul 09, 2026

Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria

Jul 09, 2026
pulisher
Jul 09, 2026

Syndax CEO Michael Metzger sells $784,776 in company stock By Investing.com - Investing.com Nigeria

Jul 09, 2026
pulisher
Jul 09, 2026

Syndax CEO Michael Metzger sells $784,776 in company stock - Investing.com

Jul 09, 2026
pulisher
Jul 09, 2026

Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo

Jul 09, 2026
pulisher
Jul 09, 2026

Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan

Jul 09, 2026
pulisher
Jul 09, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares - MarketBeat

Jul 09, 2026
pulisher
Jul 09, 2026

Syndax Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Metzger Michael A - Moomoo

Jul 09, 2026
pulisher
Jul 08, 2026

Form 144 Syndax Pharmaceuticals For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026
pulisher
Jul 08, 2026

SNDX insider files to sell 32,375 shares (NASDAQ: SNDX) - Stock Titan

Jul 08, 2026
pulisher
Jul 08, 2026

Syndax Pharmaceuticals (SNDX) TD Cowen 45th Annual Healthcare Conference Summary - Quartr

Jul 08, 2026
pulisher
Jul 08, 2026

Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next - simplywall.st

Jul 08, 2026

Syndax Pharmaceuticals Inc (SNDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$91.09
price up icon 1.97%
$118.87
price up icon 1.02%
$34.72
price down icon 0.83%
$58.73
price down icon 0.17%
ONC ONC
$325.90
price up icon 0.00%
$278.40
price up icon 2.44%
大文字化:     |  ボリューム (24 時間):